Key result
Quercetin supplementation significantly reduced systolic blood pressure (WMD -1.69; 95% CI -3.22, -0.17) in patients with metabolic syndrome, but did not affect diastolic blood pressure.
Why the study?
The study was conducted to determine the effect of quercetin administration on blood pressures and endothelial function among patients with metabolic syndrome and related disorders.
Does quercetin supplementation reduce blood pressure and improve endothelial function in patients with metabolic syndrome and related disorders?
Meta-Analysis
Does quercetin supplementation reduce blood pressure and improve endothelial function in patients with metabolic syndrome and related disorders?
Mean Difference: -1.69 (95% CI -3.22–-0.17)
Quercetin supplementation provides a modest reduction in systolic blood pressure but does not improve diastolic blood pressure or endothelial function markers in patients with metabolic syndrome.
Modest SBP reduction with quercetin in metabolic syndrome may warrant adjunctive consideration; confirms prior meta-analyses but leaves endothelial effects unresolved.
BACKGROUND: This systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to determine the effect of quercetin administration on blood pressures and endothelial function among patients with metabolic syndrome (MetS) and related disorders. METHODS: We searched systematically online databases including Cochrane Library, EMBASE, MEDLINE, and Web of Science to identify the relevant RCTs until December 2018. Q-test and I2 statistics were applied to assess heterogeneity among the included studies. Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size. RESULTS: Out of 284 citations, 8 RCTs were included in the meta-analysis. We found a significant reduction in systolic blood pressure (SBP) (WMD: -1.69; 95% CI: -3.22, -0.17) following the intake of quercetin supplements. However, quercetin supplementation did not significantly affect diastolic blood pressure (DBP) (WMD: -3.14; 95% CI: -8.24, 1.95), vascular cell adhesion molecule 1 (VCAM-1) (WMD: -24.49; 95% CI: -53.74, 4.77) and intercellular adhesion molecule 1 (ICAM-1) (WMD: -5.78; 95% CI: -12.93, 1.38). CONCLUSION: In summary, the current meta-analysis demonstrated that quercetin supplementation significantly reduced SBP, yet did not affect DBP, VCAM-1 and ICAM-1 among patients with MetS and related disorders.
No takes yet. Share an insight, caveat, or question.
Tamtaji et al. (2019) conducted a meta-analysis in Metabolic syndrome (MetS) and related disorders. Quercetin supplementation was evaluated on Systolic blood pressure (SBP) (WMD -1.69, 95% CI -3.22, -0.17). Quercetin supplementation significantly reduced systolic blood pressure (WMD -1.69; 95% CI -3.22, -0.17) in patients with metabolic syndrome, but did not affect diastolic blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: